BluntForceOptions@BluntForceOpt
$ENGN Stepped in at the lows today. Here's why.
The stock got cut by 80% on a durability print that came in softer than the Street wanted. The tape did what the tape does on a biotech disappointment day... sold first, asked questions... never. But when the dust settles and you actually run the math on what you're buying at $1.70, this is one of the cleanest setups I've seen in this space all year. Let me walk you through it.
First, the Balance Sheet
→ Cash & marketable securities: $312.5M (Q1 FY26 10-Q, as of Jan 31, 2026)
→ Market cap fully diluted at $1.78: ~$124M
→ Enterprise value: more than $130M negative, after adjusting for burn and debt drawn
→ Runway into 2H 2028
→ Plus access to up to $100M in additional Hercules tranches (milestone-gated)
Let that sink in. The market is paying you ~$130M+ to own this company. Cash alone is worth more than 2x the entire equity. Every dollar of platform value, every dollar of BLA optionality, every dollar of partnership potential... the market's handing you for free, and writing you a check on top of it.
Net cash per share alone is roughly $3.75 ish after adjusting for burn and the Hercules drawdown. That's not a price target. That's the floor underneath this stock right now, today, on the bal sheet that exists.
Which means a move from $1.78 to $3.50 is +97%... and the stock would still be trading below cash. A move to $3.75 is +110% and just gets you back to net cash per share w/the platform thrown in for free. That's not a moonshot. That's mean reversion to a number that's already on the 10-Q.
The Data: Less Bad Than the Tape Wants You to Believe
The 25% 12-month KM duration of response is what spooked the room. Fair. But context matters, and the context is being completely ignored.
Adstiladrin (Ferring) is the only approved adenoviral gene therapy in BCG-unresponsive CIS. It cleared FDA with a median duration of response of 9.7 months and ~24% of all enrolled CIS patients high-grade recurrence-free at 12 months. Long-term, only ~10% of original responders were still recurrence-free at 5 yrs. That's the existing regulatory bar... and it's not a high one.
Detalimogene's print today lands in the same neighborhood, not below it. The headline durability number isn't where this drug differentiates anyway. The other numbers from today's print are where it gets interesting:
→ 54% complete response at any time
→ 43% complete response at 6 months
→ 3.2% progression rate to muscle-invasive disease
→ 55% TRAE rate, 91% of those Grade 1-2
→ 2.4% discontinuation, 2.4% interruption
That 3.2% progression rate, in my view, is the line nobody's really talking about. It means patients stay bladder-sparing eligible. That's not a footnote -- that's a genuine clinical win in a disease where the alternative is cystectomy (full bladder removal). Doctors and patients both care deeply about this.
And the platform itself -- DDX, non-viral, shelf-stable, no cold chain -- is the real long-term asset. In community urology, where the actual prescription volume lives, that logistical profile is a genuine commercial moat. You don't need to win on raw efficacy if you win on access.
The Catalysts... Eight Days, Then 6+ Months
AUA Plenary on May 15 is the next narrative reset window. Management gets the medical community in a room and gets to reframe today's print on their terms, not the tape's terms.
BLA submission is still on the 2H 2026 path. RMAT designation. CDRP program participation. Manufacturing validation batches already complete. SAP submitted. The regulatory machinery is moving regardless of how the stock traded today.
What I'm Watching Honestly
The most recent 32-patient subgroup ran softer than the prior cohort (39% CR any time, 32% at 6mo). Mgmt says no demographic differences identified, comprehensive analysis ongoing. Real risk, eyes open.
And cretostimogene (CGON) is the durability benchmark looming over the entire space -- different commercial profile (viral, cold chain, complex logistics), but it's the comp the bears will throw at this name. I'm not pretending it doesn't exist.
Net/Net
$130M+ of negative EV. Cash floor at ~$3.75 per share. 3.2% progression rate. Real catalyst window in eight days. BLA optioned in 2H 2026. A non-viral platform with real commercial logistics advantages once you're past the initial regulatory hurdle.
IMHO, the story isn't dead. The price just got panicked. That's the trade.
Starter sized accordingly... about 1/3 position. Will reassess after May 15.
As always, just my two cents. NFA. Please do your own work. Good luck to everyone.
